Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term implantable continuous glucose monitoring systems for diabetes patients, has scheduled its second quarter 2025 earnings release and conference call for August 6, 2025.
The financial results will be released after market close, followed by a management conference call at 4:30 PM Eastern Time. Investors can access the call via phone (US/Canada: 1-800-225-9448, International: 1-203-518-9708, passcode: SENSQ2) or through a webcast available on the company's investor relations website.
Senseonics Holdings (NYSE: SENS) has successfully completed two capital raising initiatives: a public offering and a private placement. The public offering raised $57.5 million through the sale of 115 million shares at $0.50 per share, including the full exercise of underwriters' option for 15 million additional shares. Additionally, Abbott Laboratories participated in a private placement, acquiring 40.5 million shares (4.99% ownership) for $20.3 million.
The combined proceeds will fund the ongoing launch of Eversense 365, their implantable continuous glucose monitoring system for diabetes patients, pipeline product development, working capital, and general corporate purposes. The offering was managed by TD Cowen, Barclays, RBC Capital Markets, and Lake Street.
Senseonics Holdings (NYSE: SENS) has announced the pricing of a $50 million public offering of common stock, consisting of 100,000,000 shares priced at $0.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 15,000,000 shares. In a concurrent private placement, Abbott Laboratories will purchase shares at $0.50 per share, representing 4.99% of Senseonics' post-offering outstanding common stock.
The offering is expected to close on May 19, 2025, with TD Cowen and Barclays acting as joint book-running managers. The net proceeds will be used to fund the ongoing launch of Eversense 365 and pipeline product development, along with working capital and general corporate purposes.
Senseonics Holdings (NYSE: SENS) has announced a public offering of common stock aiming to raise $50 million, along with a concurrent private placement. The company will grant underwriters a 30-day option to purchase an additional 15% of the total shares offered. Abbott Laboratories has agreed to purchase up to $25 million of shares in a separate private placement at the public offering price.
The offering is being managed by TD Cowen and Barclays as joint book-running managers, with RBC Capital Markets and Lake Street as bookrunners. The proceeds will be used to fund the ongoing launch of Eversense 365, continue pipeline product development, and support working capital and general corporate purposes.
Senseonics Holdings, a pioneer in medical technology focusing on implantable continuous glucose monitoring (CGM) systems for diabetes patients, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss Q1 2025 performance. Investors can participate through multiple channels:
- Conference call: US/Canada: 1-800-343-4136
- International: 1-203-518-9843
- Passcode: SENSQ1
- Webcast: Available on www.senseonics.com under Investor Relations
The webcast will be archived on the company's website for future reference. Participants are advised to dial in 5-10 minutes before the start time.
Sequel Med Tech and Senseonics have partnered to create the first Automated Insulin Delivery (AID) System compatible with a one-year continuous glucose monitor. The integration combines Sequel's twiist™ AID System with Senseonics' Eversense® 365, the world's first and only one-year CGM system.
Key highlights:
- Launch expected in Q3 2025
- System offers enhanced diabetes management tools
- twiist will be compatible with both Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor
- Eversense 365 received FDA iCGM clearance in September 2024
The collaboration aims to provide greater flexibility and personalization for people with type 1 diabetes. This integration marks a significant advancement in diabetes care, combining Senseonics' long-duration CGM technology with Sequel's state-of-the-art insulin delivery system to potentially improve glucose control and increase convenience for users.
Senseonics Holdings (NYSE: SENS) reported Q4 and full year 2024 financial results, highlighting significant achievements in their diabetes care technology. The company's Eversense® 365 CGM system received FDA approval and launched in the US, leading to a 56% increase in global patient base to approximately 6,000 patients.
Q4 2024 revenue reached $8.3 million with a net loss of $15.5 million ($0.02 per share). Full-year 2024 revenue was $22.5 million with a net loss of $78.6 million ($0.12 per share). December marked the highest monthly new patient shipments at approximately 600.
Key highlights include:
- Exceeded 2,400 annual US Eversense prescribers in 2024
- 81% of patients switched from competitive CGMs
- Completed CE Mark application for Eversense 365 in EU
- Executed restructuring with $10M target cost reduction for 2025
For 2025, Senseonics projects global net revenue of $34-38 million with gross margins between 25-30%.
Senseonics Holdings (NYSE: SENS) and Ascensia Diabetes Care have announced the integration of SweetSpot™ software with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This integration enables endocrinology practices partnered with SweetSpot to enhance patient care through seamless data review from the world's first and only One Year CGM system.
SweetSpot's platform combines centralized diabetes device data management with clinical support services. Their virtual team of Certified Diabetes Care and Education Specialists performs monthly CGM data reviews and coordinates with healthcare providers on treatment plans. The integration allows for personalized support between appointments and helps ensure timely treatment adjustments.
The partnership aims to improve glycemic control while offering practices automated capture of reimbursable care events. Eversense 365, developed by Senseonics and distributed by Ascensia, provides one year of accurate monitoring with minimal interruptions as the only implantable CGM available.